[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342204-105":59,"doc-detail-342204-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","il-17a-in-gastric-carcinogenesis-good-or-bad-review","IL-17A in gastric carcinogenesis: good or bad? - Review","","Review of current evidence on IL-17A in gastric carcinogenesis, focusing on how cytokines within the tumor microenvironment (TME) influence gastric tumor development, metastasis, and immune responses. Elevated IL-17 and sustained Th17 activity are discussed in relation to precancerous stomach conditions, while IL-17A is presented as having a dual role—promoting processes such as proliferation, angiogenesis, and immune-cell recruitment or suppressing growth via antitumor immunity. The review also evaluates IL-17-targeted immunotherapy, including limitations from clinical trial scarcity and tumor heterogeneity, and outlines needs for deeper mechanistic studies and targeted therapeutic design.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/il-17a-in-gastric-carcinogenesis-good-or-bad-review/342204/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/il-17a-in-gastric-carcinogenesis-good-or-bad-review/342204.png","ImageObject",300,407,{"name":92,"@type":93},"Clementine","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What makes IL-17A relevant to gastric carcinogenesis?","Question",{"text":112,"@type":113},"IL-17A is linked to cytokine-driven tumor microenvironment changes and immune responses. Higher IL-17 levels are observed in gastric disease contexts such as Helicobacter pylori infection and autoimmune gastritis, suggesting Th17 activity may precede cancer development.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How can IL-17A play both pro-tumor and anti-tumor roles?",{"text":117,"@type":113},"The document explains that IL-17A can promote tumor development through mechanisms like boosting proliferation, inducing angiogenesis, and recruiting immune cells. It can also suppress tumor growth by activating antitumor immune responses, depending on the TME and immune-cell composition.",{"name":119,"@type":110,"acceptedAnswer":120},"Why is IL-17A immunotherapy for gastric cancer still uncertain?",{"text":121,"@type":113},"The therapeutic potential is described as hindered by IL-17’s diverse activities and by mixed evidence on whether anti-IL-17 approaches are beneficial. The lack of clinical trials and the heterogeneity of human tumors also underscore the need for individualized treatment strategies.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},342204,1790252881,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},1374391974564,"https://ap-avatar.wpscdn.com/avatar/14000253aa45c000a9e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779874745381141002","TYPE Review  \nPUBLISHED 29 November 2024 DOI 10.3389/fimmu.2024.1501293  \nOPEN ACCESS  \nEDITED BY  \nZong Sheng Guo,  \nUniversity at Buffalo, United States  \nREVIEWED BY  \nJonadab Efrain Olguin Hernandez, National Autonomous University of Mexico, Mexico  \nGuohua Xie,  \nShanghai Jiao Tong University, China  \n*CORRESPONDENCE  \nHao Chen  \n [ery_chenh@lzu.edu.cn](ery_chenh@lzu.edu.cn)  \n†These authors have contributed equally to this work  \nRECEIVED 24 September 2024  \nACCEPTED 13 November 2024  \nPUBLISHED 29 November 2024  \nCITATION  \nLi W, Huang X, Han X, Zhang J, Gao L and Chen H (2024) IL-17A in gastric carcinogenesis: good or bad?  \nFront. Immunol. 15:1501293 .  \ndoi: 10.3389/fimmu.2024.1501293  \nCOPYRIGHT  \n© 2024 Li, Huang, Han, Zhang, Gao and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nIL-17A in gastric carcinogenesis: good or bad?  \nWeidong Li 1†, Xiaodong Huang 1†, Xiaowen Han 1†, Jiayi Zhang 1†, Lei Gao 1 and Hao Chen 1,2*  \n1 Department of Surgical Oncology, Lanzhou University Second Hospital, Lanzhou, China, 2 Key Laboratory of Environmental Oncology of Gansu Province, Lanzhou University Second Hospital, Lanzhou, China  \nCytokines, which are important to the tumor microenvironment (TME), play critical roles in tumor development, metastasis, and immune responses . Interleukin-17(IL-17) has emerged as a key biomarker in many malignancies; however, its precise involvement in gastric cancer is less fully understood. Elevated levels of IL-17 have been observed in stomach diseases such as Helicobacter pylori infection and autoimmune gastritis, indicating that a sustained Th17 response may precede the development of gastric cancer. While IL-17 is related to inﬂammatory processes that may lead to cancer, its speciﬁc inﬂuence on gastric cancer development and therapy needs to be completely understood. Speciﬁcally, the release of IL-17A by diverse immune cells has been associated with both tumor development and inhibition in gastric cancer. It may impact tumor development through mechanisms such as boosting cell proliferation, inducing angiogenesis, and enabling immune cell recruitment or, conversely, suppressing tumor growth via the activation of antitumor immune responses. The dual role of IL-17 in cancer, along with its various effects depending on the TME and immune cell composition, highlights the complexity of its activity. Current research reveals that although IL-17 might serve as a target for immunotherapy, its therapeutic potential is hindered by its various activities. Some studies have shown that anti-IL-17 drugs may be helpful, especially when paired with immune checkpoint inhibitors, whereas others point to concerns about the validity of IL-17 in gastric cancer therapy. The lack of clinical trials and the heterogeneity of human tumors underscore the necessity for individualized treatment approaches. Further studies are needed to identify the speciﬁc mechanisms of IL-17 in gastric cancer and to design targeted therapeutics appropriately.  \nKEYWORDS  \ngastric cancer, IL-17, tumor microenvironment, Helicobacter pylori, immunotherapy  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \nIntroduction  \nCytokines play crucial roles in the development of the TME, affecting tumor growth, metastasis, and immune responses (1–4) . Robust preclinical evidence supports therapeutic strategies aimed at enhancing the growth-inhibitory and immune-stimulatory effects of interferons and interleukins (including IL-2, IL-7, IL-12, and IL-15) or inhibiting the inﬂammatory and protumor effects of cytokines such as tumor","cbCailxNvTYZ8rkS","https://ap.wps.com/l/cbCailxNvTYZ8rkS","pdf",2553196,12,"English","# Introduction\n## IL-17\n# Key roles of IL-17A in gastric carcinogenesis\n## Dual function in the tumor microenvironment\n## Implications for targeted and immunotherapy","[{\"question\":\"What makes IL-17A relevant to gastric carcinogenesis?\",\"answer\":\"IL-17A is linked to cytokine-driven tumor microenvironment changes and immune responses. Higher IL-17 levels are observed in gastric disease contexts such as Helicobacter pylori infection and autoimmune gastritis, suggesting Th17 activity may precede cancer development.\"},{\"question\":\"How can IL-17A play both pro-tumor and anti-tumor roles?\",\"answer\":\"The document explains that IL-17A can promote tumor development through mechanisms like boosting proliferation, inducing angiogenesis, and recruiting immune cells. It can also suppress tumor growth by activating antitumor immune responses, depending on the TME and immune-cell composition.\"},{\"question\":\"Why is IL-17A immunotherapy for gastric cancer still uncertain?\",\"answer\":\"The therapeutic potential is described as hindered by IL-17’s diverse activities and by mixed evidence on whether anti-IL-17 approaches are beneficial. The lack of clinical trials and the heterogeneity of human tumors also underscore the need for individualized treatment strategies.\"}]","IL-17A in gastric carcinogenesis: good or bad? - Review | PDF",1790045759,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/39b7c4fad508b3fbf95ae794244741e6.webp",983,1389,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/524cf8a7a9297351a5759351a3128dc8.webp",982,1388,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bae7b201ca03af322d6b400339ca422e.webp",981,1386,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fdd74373e33a65adad762a628a76c2e0.webp",980,1385]